Ernexa Therapeutics Inc. (ERNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.84M
Last updated: Nov 17, 2026 at 11:04 AM ET
Ernexa Therapeutics Inc. (ERNA) Earnings: Report Dates and Results
Ernexa Therapeutics (ERNA) is expected to report earnings on Mar 11, 2027. In the quarter ended Sep 30, 2026, Ernexa Therapeutics reported EPS of -$1.89, above the -$3.84 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ERNA has an expected report date of Mar 11, 2027. No consensus estimate is on file yet for the quarter ending Mar 31, 2027.
Earnings History
Of the 22 quarters below that had an estimate, ERNA beat 8, missed 13 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2023, when EPS landed 785.71% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.89 | -$3.84 | -$3.84 - -$3.84 | +50.78% | Beat | N/A | 1 | 0 up, 0 down | Nov 6, 2026 | N/A |
| Jun 30, 2026 | -$3.40 | -$3.30 | -$3.30 - -$3.30 | -3.03% | Miss | N/A | 1 | 0 up, 0 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$6.95 | -$1.95 | N/A | -256.41% | Miss | N/A | N/A | N/A | May 11, 2026 | N/A |
| Dec 31, 2025 | -$4.81 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 13, 2026 | N/A |
| Sep 30, 2025 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 7, 2025 | N/A |
| Jun 30, 2025 | -$0.61 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2025 | N/A |
| Mar 31, 2025 | -$2.31 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 7, 2025 | N/A |
| Dec 31, 2024 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Mar 13, 2025 | $1000 |
| Sep 30, 2024 | -$1,844.09 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Nov 12, 2024 | $487000 |
| Jun 30, 2024 | -$383.80 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Aug 13, 2024 | $47000 |
| Mar 31, 2024 | -$460.74 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | May 13, 2024 | $47000 |
| Dec 31, 2023 | -$427.06 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Mar 13, 2024 | $17000 |
| Sep 30, 2023 | -$1.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 13, 2023 | $51000 |
| Jun 30, 2023 | -$0.85 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2023 | N/A |
| Mar 31, 2023 | -$1.24 | -$0.14 | N/A | -785.71% | Miss | N/A | N/A | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$1.24 | -$0.14 | N/A | -785.71% | Miss | N/A | N/A | 0 up, 0 down | Mar 20, 2023 | N/A |
| Sep 30, 2022 | -$933.75 | -$825.00 | N/A | -13.18% | Miss | N/A | 1 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$450.00 | -$975.00 | N/A | +53.85% | Beat | N/A | N/A | N/A | Jul 1, 2022 | N/A |
| Mar 31, 2022 | -$3.20 | -$3.13 | N/A | -2.35% | Miss | -16100.0% | N/A | N/A | Apr 15, 2022 | N/A |
| Dec 31, 2021 | -$3.20 | -$3.13 | N/A | -2.35% | Miss | -3300.0% | N/A | N/A | Dec 31, 2021 | N/A |
| Sep 30, 2021 | -$12,749.99 | -$12,000.00 | N/A | -6.25% | Miss | -63750050.0% | N/A | N/A | Nov 9, 2021 | N/A |
| Jun 30, 2021 | -$0.24 | N/A | N/A | N/A | N/A | -1300.0% | N/A | N/A | Aug 13, 2021 | N/A |
| Mar 31, 2021 | $0.02 | N/A | N/A | N/A | N/A | 0.0% | N/A | N/A | May 17, 2021 | N/A |
| Dec 31, 2020 | $0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 11, 2021 | $5.80M |
| Sep 30, 2020 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 11, 2020 | N/A |
| Jun 30, 2020 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 7, 2020 | N/A |
| Mar 31, 2020 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 19, 2020 | $2.39M |
| Dec 31, 2019 | -$0.45 | $0.01 | N/A | N/A | N/A | -110.2% | N/A | N/A | Mar 19, 2020 | $9.75M |
| Sep 30, 2019 | -$0.12 | -$0.03 | N/A | -300.00% | Miss | -103.8% | N/A | N/A | Oct 10, 2019 | N/A |
| Jun 30, 2019 | -$0.03 | -$0.03 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 9, 2019 | $5.23M |
| Mar 31, 2019 | -$0.11 | $0.20 | N/A | -155.00% | Miss | N/A | N/A | N/A | May 13, 2019 | $4.83M |
| Dec 31, 2018 | $4.40 | $6.00 | N/A | -26.67% | Miss | N/A | N/A | N/A | Mar 20, 2019 | $5.92M |
| Sep 30, 2018 | $3.20 | -$1.60 | N/A | +300.00% | Beat | N/A | N/A | N/A | Nov 7, 2018 | $6.00M |
| Jun 30, 2018 | -$2.00 | -$9.20 | N/A | +78.26% | Beat | N/A | N/A | N/A | Aug 2, 2018 | $5.65M |
| Mar 31, 2018 | -$6.40 | -$5.40 | N/A | -18.52% | Miss | N/A | N/A | N/A | May 9, 2018 | $5.76M |
| Dec 31, 2017 | -$10.00 | -$11.20 | N/A | +10.71% | Beat | N/A | N/A | N/A | Mar 6, 2018 | $5.30M |
| Sep 30, 2017 | -$2.80 | -$8.40 | N/A | +66.67% | Beat | N/A | N/A | N/A | Nov 7, 2017 | $5.20M |
| Jun 30, 2017 | -$2.80 | -$14.00 | N/A | +80.00% | Beat | N/A | N/A | N/A | Aug 2, 2017 | $5.55M |
| Mar 31, 2017 | -$1.60 | -$15.60 | N/A | +89.74% | Beat | N/A | N/A | N/A | May 3, 2017 | $5.23M |
| Dec 31, 2016 | -$8.80 | -$7.60 | N/A | -15.79% | Miss | N/A | N/A | N/A | Mar 6, 2017 | $5.98M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$7.88, after -$2,688.78 the year before. It was -$62.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$7.88 | N/A |
| Dec 31, 2024 | -$2,688.78 | N/A |
| Dec 31, 2023 | -$430.18 | N/A |
| Dec 31, 2022 | -$1,388.19 | N/A |
| Dec 31, 2021 | -$12,753.41 | -7970981.3% |
| Dec 31, 2020 | $0.16 | N/A |
| Dec 31, 2019 | -$0.71 | N/A |
| Dec 31, 2018 | -$0.80 | N/A |
| Dec 31, 2017 | -$17.20 | N/A |
| Dec 31, 2016 | -$62.00 | N/A |
Frequently Asked Questions About ERNA
When is Ernexa Therapeutics's next earnings date?
Ernexa Therapeutics's next earnings report is expected for Mar 11, 2027.
Did ERNA beat earnings estimates last quarter?
Yes. Ernexa Therapeutics reported EPS of -$1.89 for the quarter ended Sep 30, 2026, above the -$3.84 estimate, a 50.78% surprise.
How often does ERNA beat earnings estimates?
Ernexa Therapeutics beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -217.72%.
ERNA pages: Overview, Earnings, Forecast, Financials, Competitors